Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

Other analysts have also issued reports about the stock. TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Thursday, August 9th. Royal Bank of Canada set a $64.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 2nd. Cantor Fitzgerald set a $81.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 24th. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. Finally, Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Eagle Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $77.17.

Shares of Eagle Pharmaceuticals stock opened at $47.13 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. The stock has a market capitalization of $702.86 million, a P/E ratio of 13.99 and a beta of 1.71. Eagle Pharmaceuticals has a 1 year low of $46.38 and a 1 year high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.27. The company had revenue of $51.34 million during the quarter, compared to analyst estimates of $52.70 million. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. Eagle Pharmaceuticals’s quarterly revenue was down 18.5% compared to the same quarter last year. During the same period last year, the business earned $1.22 EPS. Equities research analysts expect that Eagle Pharmaceuticals will post 2.03 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at about $108,000. Macquarie Group Ltd. increased its stake in Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,200 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at about $115,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $150,000. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at about $156,000.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Further Reading: How accurate is the Rule of 72?

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.